MoonLake Q3 R&D rose to $68.9 million as cash ended quarter at $498.5 million
MoonLake reported third quarter 2026 results and a business update, including submission of a Biologics License Application for sonelokimab in hidradenitis suppurativa on September 30, 2026. Research and development expenses rose to $68.9 million, mainly from accrued milestone license fees tied to the expected BLA acceptance, while the company reported cash, cash equivalents and short-term marketable debt securities of $498.5 million and a cash runway to mid-2028. The filing does not report revenue or earnings per share.
Key points
- R&D expenses were $68.9 million for the quarter ended September 30, 2026, up $18.7 million from $50.2 million in the prior quarter, mainly from accrued milestone license fees.
- G&A expenses were $11.0 million, compared with $11.4 million in the prior quarter.
- Cash and short-term marketable debt securities were $498.5 million as of September 30, 2026, with a cash runway expected to mid-2028.
- The company expects a decision on BLA acceptance by the end of November 2026 and up to $400 million more is available through its Hercules Capital debt facility.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.